Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Reynolds

Showing results (191-200 of 212) with videos related to

Pageof 22
Sort By:
Frontiers in Immunology|July 4, 2018
A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931M Fevzi Ozkaynak, Andrew L Gilman, Wendy B London, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2011
Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology GroupJudith G Villablanca, Wendy B London, Arlene Naranjo, et al.
Frontiers in Immunology|July 27, 2018
Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931M Fevzi Ozkaynak, Andrew L Gilman, Wendy B London, et al.
The Lancet. Oncology|July 30, 2013
Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trialSusan G Kreissman, Robert C Seeger, Katherine K Matthay, et al.
Cancer Research|April 16, 2020
Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk NeuroblastomaBalakrishna Koneru, Gonzalo Lopez, Ahsan Farooqi, et al.
Cancer Chemotherapy and Pharmacology|March 31, 2011
Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancerHernan Carol, Ingrid Boehm, C Patrick Reynolds, et al.
Oncotarget|September 9, 2017
A comprehensively characterized cell line panel highly representative of clinical ovarian high-grade serous carcinomasKelsie L Thu, Mahboubeh Papari-Zareei, Victor Stastny, et al.
Neuro-Oncology|February 12, 2025
High-throughput in vitro drug screening and in vivo studies identify fenretinide as a brain-penetrant DMG therapeuticDannielle H Upton, Jie Liu, Sandra M George, et al.
The EMBO Journal|February 25, 2022
Reduced ER-mitochondria connectivity promotes neuroblastoma multidrug resistanceJorida Çoku, David M Booth, Jan Skoda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2010
Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II studySuzanne Shusterman, Wendy B London, Stephen D Gillies, et al.
Pageof 22

Showing results (191-200 of 212) with videos related to

Sort By:
Pageof 22
Frontiers in Immunology|July 4, 2018
A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931M Fevzi Ozkaynak, Andrew L Gilman, Wendy B London, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2011
Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology GroupJudith G Villablanca, Wendy B London, Arlene Naranjo, et al.
Frontiers in Immunology|July 27, 2018
Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931M Fevzi Ozkaynak, Andrew L Gilman, Wendy B London, et al.
The Lancet. Oncology|July 30, 2013
Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trialSusan G Kreissman, Robert C Seeger, Katherine K Matthay, et al.
Cancer Research|April 16, 2020
Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk NeuroblastomaBalakrishna Koneru, Gonzalo Lopez, Ahsan Farooqi, et al.
Cancer Chemotherapy and Pharmacology|March 31, 2011
Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancerHernan Carol, Ingrid Boehm, C Patrick Reynolds, et al.
Oncotarget|September 9, 2017
A comprehensively characterized cell line panel highly representative of clinical ovarian high-grade serous carcinomasKelsie L Thu, Mahboubeh Papari-Zareei, Victor Stastny, et al.
Neuro-Oncology|February 12, 2025
High-throughput in vitro drug screening and in vivo studies identify fenretinide as a brain-penetrant DMG therapeuticDannielle H Upton, Jie Liu, Sandra M George, et al.
The EMBO Journal|February 25, 2022
Reduced ER-mitochondria connectivity promotes neuroblastoma multidrug resistanceJorida Çoku, David M Booth, Jan Skoda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2010
Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II studySuzanne Shusterman, Wendy B London, Stephen D Gillies, et al.
Pageof 22